Portfolio CLARA Proof of Concept projects

CLARA TCLARA TRANSFERRANSFER::FFROMROM RRESEARCHESEARCH TOTO AAPPLICATIONPPLICATION ININ OONCOLOGYNCOLOGYFFROMROM RRESEARCHESEARCH TOTO AAPPLICATIONPPLICATION ININ OONCOLOGYNCOLOGY

A PUBLIC ‐ PRIVATE PARTNERSHIP BETWEEN

RESEARCHERS, CLINICIANS AND ENTREPRENEURS

CLARA TRANSFER: A UNIQUE PROGRAM TO SUPPORTTHE TRANSFER OF CANCER RESEARCH FINDINGS

At the critical stage of cancer research when academic financing and expertise become insufficient,CLARA Transfer brings in funding and specialized networks to perform the Proof of Concept studies

3

CLARA Transfer brings in funding and specialized networks to perform the Proof of Concept studiesthat will convince partners to proceed with clinical and industrial development.

SSUPORTINGUPORTING PPROMISINGROMISING ANDAND IINNOVATIVENNOVATIVE PPROJECTSROJECTS

TTOWARDSOWARDS IINDUSTRIALNDUSTRIAL ANDAND CCLINICALLINICAL TTRANSFERRANSFERTTOWARDSOWARDS IINDUSTRIALNDUSTRIAL ANDAND CCLINICALLINICAL TTRANSFERRANSFER

Clearly Focused Projects• Pre‐clinical and/or clinical Proof of Concept

• Industrial and Clinical transferIndustrial and Clinical transfer

Project with Solid Foundations• Clear and obtainable candidate or prototype to be tested and developedp yp p

• Established Intellectual Property

• Clear transfer and development strategy, led by the partner company

Complementary Partners and leadership in CLARA's region• Academic and clinical partners

• Start‐up or Innovative company with a clear development plans in the Regionp p y p p g

• Open to partners beyond CLARA boarders (funding to be determined)

High medical and industrial interest for oncology• Therapeutics, Devices, Diagnostics, Technologies…

4

CLARA TCLARA TRANSFERRANSFER: : PPERSONALIZEDERSONALIZED AASSISTANCESSISTANCE ANDAND DDEVELOPMENTEVELOPMENT SSUPPORTUPPORTPPERSONALIZEDERSONALIZED AASSISTANCESSISTANCE ANDAND DDEVELOPMENTEVELOPMENT SSUPPORTUPPORT

Significant & Flexible Financing*

Personalized Assistance Financing*Assistance

Academic and Clinical Costs

CLARAT f

Industrial Costs

IndustrialP t

Dedicated Team Senior

Development

Large Network of Partners & Contractors Transfer Partner

Aft P f f C t

ExpertsCo ac o s

After Proof of Concept:• Pursuit of project by the partner company

• Royalties for academic and clinical partners

• Commitment from the company to reinvest in CLARA R&D

5

• Commitment from the company to reinvest in CLARA R&D

* Average budget per project: €1.2M including €600K from the Cancéropôle CLARA

KKEYEY NNUMBERSUMBERS ANDAND RRESULTSESULTS OFOF CLARACLARA TRANSFERTRANSFERKKEYEY NNUMBERSUMBERS ANDAND RRESULTSESULTS OFOF CLARA CLARA TRANSFERTRANSFER

30 projects supported since 2005 • 20 ongoing projects• 7 successful Proof of Concept projects completed

10 Advanced Projects

• 7 successful Proof of Concept projects completed

Budget: €36M 10 Advanced Projects• 1 on the market• 5 in clinical development• 4 validated at pre‐clinical

g• Public Authorities & European ERDF Funds (€11M)

• Partnering Companies (€25M) 4 validated at pre‐clinicallevel

70+ Partners Involved• 43 Academics• 7 Clinical Centers

22 Innovative Companies• 7 Start‐ups

• 7 companies raised €90M

6

7 Clinical Centers• 22 Companies

p

• 1 foreign company subsidiary establishment (Japan)

CLARA TCLARA TRANSFERRANSFER: : SSEVENEVEN PPROOFROOF OOFF CCONCEPTONCEPT PPROJECTSROJECTS CCOMPLETEDOMPLETEDSSEVENEVEN PPROOFROOF OOFF CCONCEPTONCEPT PPROJECTSROJECTS CCOMPLETEDOMPLETED

Clinical Proof of Concept:

• ViKY, Mini‐Robot for Solid Cancers Laparoscopic Surgery (First success story in 2009)• High‐Intensity Focused Ultrasound Device for the Treatment of Liver Metastases from

Colorectal Cancer (Preclinical POC and AFSSAPS agreement in 2009, Clinical phase IIa ongoing)

Preclinical Proof of Concept:Preclinical Proof of Concept:

• Photosensitive Nanoparticles for Glioblastoma Treatment (2009)

• Lung Cancer Therapeutic Targeting with TLR3 Receptor Agonists (2009)

• Mini‐Invasive Biopsy Tool for Non‐Lesional Cellular and Proteic Footprints of Tumoral Nodes(2010)

• Hybrid Nanoprobes as Imaging Agents to Trace Cells in the Course of Cellular TherapyProtocoles in Melanoma (2011)Protocoles in Melanoma (2011)

• Fluorescence Imaging Device for Peroperative Detection of Tumor Margins and Metastases inSarcomas (2012)

7

CLARA TRANSFER ‐ ADVANCED PROOF OF CONCEPT PROJECTSMARKETED OR IN CLINICAL DEVELOPMENT

Acronym and Title of Project

Cancer Types Academic & ClinicalPartners

Partner Company

Budget Stage of Develop‐ment

SeePage

ViKY: Light endoscopic robot for laparoscopic cancer surgery

Prostate, liver, pancreas, colon, lung

‐ TIMC Lab (CNRS 5525, UJF), Grenoble

EndoControlMedical,Grenoble

2007‐2009: €425K

€212K CLARA€213K Endocontrol

Marketed(Europe, USA)

13

HIFU: High Intensity Focused l d d f h

Liver metastasis f l l

‐ LabTAU, Inserm, Lyoné é d

EDAP TMS, 2007‐2012: €1.1M Phase IIb 14Ultrasound device for the treatment of liver metastases from colorectal cancer

from colorectal cancer

‐ Léon Bérard Cancer Center, Experimental Surgery Institute, Inserm, Lyon

Lyon €535K CLARA€565K EDAP TMS

ongoing

Lymphos'1: Low T‐CellReceptors Diversity (Divpenia)

Metastatic Breast and Lung

‐Cancer Research Center, Lyon‐Léon Bérard Cancer Center,

ImmunIDTechnologies,

2008‐2012: €850K

€425K CLARA

Clinicalprospective

15p y ( p )

Combined with Lymphopeniapredicts poor Overall Survival in Metastatic Breast Cancer Patients

gcancers

,Lyon

g ,Grenoble

€425K CLARA€425K ImmunID

p pstudies ongoing

S f i I ti R di S i l Lé Bé d C C t O Th 2010 2014 €6 3M Cli i l h I 16Synfrizz: Innovative Radio‐immunotherapy for synovialo‐sarcoma treatment, targetingFZD10 functionnal and specificantigen

Synovialo‐sarcoma

‐ Léon Bérard Cancer Center,Lyon

OncoTherapyScience, Lyon

2010‐2014: €6.3M

€751K CLARA€5.6M OncoTherapyScience

Clinical phase I ongoing

16

Enki‐HEH: New endoscopicresection device for superficial colorectal, gastricand esophageal neoplasms

Superficialcolorectal, gastricand esophagealneoplasms

‐ Lyon University Hospital(HCL)

NESTIS, Lyon 2011‐2012: €350K

€140K CLARA€206K NESTIS

Clinical phase I ongoing

17

GeniusVac Mel4: Therapeutic Melanoma Joseph Fourier University French 2011 2015: €1 7M Clinical Trial 18GeniusVac‐Mel4: Therapeuticvaccine based on dendriticcells to treat metastaticmelanoma

Melanoma ‐ Joseph Fourier University, French National Blood Service, INSERM, University HospitalCenter, Grenoble

French National Blood Service (EFS), Grenoble

2011‐2015: €1.7M

€698K CLARA€1M EFS

Clinical Trial AuthorizationApplication ongoing

18

8

CLARA TRANSFER ‐ COMPLETED PRECLINICAL PROOF OF CONCEPT PROJECTSTO BE TRANSLATED INTO CLINICAL TRIALS



Partner Company


SeePage

ment

GanglioTool: Mini‐invasive biopsy tool for non lesionalcellular and proteic footprintof tumoral nodes

Lymphoma, Metastatic mediastinalnodes

‐ CEA/LETI, Grenoble‐ CEA/Clinatec, Grenoble teaching hospital, GIN‐ Lyon Civil Hospitals

CEA, Grenoble 2008‐2010: €380K

€250 K CLARA€130K CEA

‐ Preclinical POCcompleted‐ Clinical trial dossier in d l

9

‐ Saint‐Etienne University Hospital

development

Claraft: Fluorescence imagingdevice for peroperativedetection of tumor margins

Sarcoma ‐ Léon Bérard Cancer Center, Lyon‐Albert Bonniot Institute,

Fluoptics, Grenoble

2010‐2012: 1M€

€508K CLARA€510K Fluoptics

‐ Preclinical POC completed‐ Clinical trial

20

detect o o tu o a g sand metastases in sarcomas

be t o ot st tute,Inserm, Joseph Fourier University, Grenoble‐Veterinary SchoolVetAgroSup, Lyon

€510K Fluoptics C ca t adossier in development

NSH H b id b M l L Ci il H it l UCBL N H S i t 2007 2011 €615K P li i l POC 21NSH: Hybrid nanoprobes as imaging agents to trace cells in the course of cellular therapy protocoles in melanoma

Melanoma ‐ Lyon Civil Hospitals, UCBL Nano‐H, Saint‐Quentin Fallavier

2007‐2011: €615K

€307K CLARA€308K Nano‐H

Preclinical POC completed

21

9

CLARA TRANSFER ‐ ONGOING PRECLINICAL PROOF OF CONCEPT PROJECTSTHERAPEUTIC MOLECULES


CancerTypes

Academic & ClinicalPartners

Partner Company


SeePage

ment

CANCERDRUG: Preclinicalvalidation of a novel vasculardisrupting agent (VDA) targetingPP1

Vascularized solidtumors

‐ Grenoble Neurosciences Institute, Inserm, University of Grenoble‐ Curie Institute, Paris

EcrinsTherapeutics,Grenoble

2010‐2012: €1M

€628K CLARA€407K Ecrins Therapeutics

Preclinical POC ongoing

22

IPROMAH: Humanized therapeutic monoclonal antibodies against CD5 and CD19 for non‐hodgkin'slymphomas

Non‐hodgkin'slymphomas

Lyon Civil Hospitals, Lyon University, Lyon Cancer Research Center

iDD Biotech, Dardilly

2009‐2012: €1M

€354K CLARA€646K IDD Biotech


23

LANTHARAD: Targeted hybrid Melanoma ‐ Lyon Civil Hospitals UCBL Nano‐H Saint‐ 2009‐2012: €615K Preclinical POC 24LANTHARAD: Targeted hybrid radiosensitizer nanoparticles for radiotherapy of melanoma and chondrosarcoma

Melanoma, Chondro‐sarcoma, Head and Neck, Gliosarcoma

‐ Lyon Civil Hospitals, UCBL, LPCML, Lyon‐ Inserm U990, Clermont‐Ferrand

Nano‐H, Saint‐Quentin Fallavier

2009‐2012: €615K

€404K CLARA€211K Nano‐H


24

LIPOBAK: Bak protein associated Glioblastoma TheRex Laboratory Joseph Synthélis 2010 2013: €430K Preclinical POC 25LIPOBAK: Bak protein associatedproteoliposomes for glioblastomatreatment

Glioblastoma ‐TheRex Laboratory, Joseph Fourier University (UJF), Grenoble‐ Neurobiology and TransgenesisLaboratory, Angers

Synthélis,Grenoble

2010‐2013: €430K

€228K CLARA€206K Synthélis


25

10

CLARA TRANSFER ‐ ONGOING PRECLINICAL PROOF OF CONCEPT PROJECTSTHERAPEUTIC MOLECULES


CancerTypes

Academic & ClinicalPartners

Partner Company


SeePage

ment

NETRIS: Drug candidates based on Dependence Receptors concept inhibiting Netrin‐1/DCC‐UNC5 in lung cancer and NT‐3/TrkC in metastatic breast cancer

Lung, Metastatic breast cancer

Lyon Cancer Research Center, Léon Bérard Cancer Center, Lyon

Netris Pharma, Lyon

2008‐2012: €1.6M

€800K CLARA€800K Netris Pharma


26

metastatic breast cancer

THERA 8: Targeting cell surface CK8 for the development of therapeutic antibodies for colorectal cancers

Colo‐rectal cancer (CCR)

Lyon Cancer Research Center (CRCL)

IDD biotech, Dardilly

2011‐2014: € 713K€ 354K CLARA€ 359K IDD biotech


27

TRT/PETMEL: Development of heteroaromatic halogenated molecules for either PET or SPECT imaging and Targeted Radionuclide Therapy of metastatic melanoma

Metastatic melanoma

UMR 990 Inserm, Auvergne University, Clermont‐Ferrand

CyclopharmaLaboratories, Clermont‐Ferrand

2009‐2013: €830K

€416K CLARA€414K Cyclopharma


28

Therapy of metastatic melanoma

11

CLARA TRANSFER ‐ ONGOING PRECLINICAL PROOF OF CONCEPT PROJECTSSURGICAL DEVICES



Partner Company


SeePage

ment

Doc Calipso: Robot navigation for small tumor focal therapy

Small solid tumors ‐ Lyon 1 Claude Bernard University, Lyon Civil Hospitals

ADEPT, Annecy 2010 to 2013: €1.3M

€627K CLARA€629K ADEPT


29

Hépatofluo: Indocyanine Green as a near‐infrared fluorescent contrast agent and mini‐camera Fluobeam® for image‐guidedliver surgery

Liver cancer and metastases

‐ Léon Bérard Cancer Center,Lyon

Fluoptics, Grenoble

2011‐2014: €1M

€498K CLARA€498K Fluoptics


30

Nano Eno: Nanoencapsulatednuclear/optical imaging probe

Solid tumors ‐ CEA, Grenoble & Orsay‐ Veterinary SchoolVetAgroSup, Lyon

Advanced Accelerator Applications (AAA), Saint‐Genis Pouilly

2010‐2013: €700K

€426K CLARA€269K AAA


31

Uroclip: Automatic uretro‐vesicalanastomosis system in prostate cancer

Prostate cancer ‐ Veterinary SchoolVetAgroSup, Lyon

Anastom Surgical,Lyon

2011‐2013: €400K

€278K CLARA€118K Anastom‐Surgical


32

12

C S (€ 2 )

Surgical Device Clinical POC CompletedMarketed (USA, Europe)

Prostate, Liver, Pancreas, Colon, Lung…

VIKY: ENDOSCOPIC ROBOT FOR LAPAROSCOPIC CANCER SURGERY (€425K)

CONCEPT• A light and intelligent robotic endoscope holder for

MAIN RESULTS• 3 patents

laparoscopic surgery, with either voice or foot controlby surgeon

• Added Value: Light, easy, low cost; reduces personnelneeds, freeing staff for alternative operating roomtasks and reducing the need for personnel allowing

• European CE mark and AFSSAPS agreement (2009)

• Clinical validation in 300 laparoscopic surgical procedures,including complex cancer surgeries (prostate, liver,pancreas, colon, lung…), proved that ViKY is at least assecure and efficient as human surgeon assistants with atasks and reducing the need for personnel, allowing

one of them to perform other tasks in the operatingroom

secure and efficient as human surgeon assistants with apositive influence on the quality of the surgery.

ACADEMIC/CLINICAL PARTNERS• J TROCCAZ TIMC Lab (CNRS 5525 UJF Grenoble)

PROSPECTS• Further collaboration and development of new innovative• J. TROCCAZ, TIMC Lab (CNRS 5525, UJF, Grenoble)

• 4 clinical cancer centers

psolutions for robotic laparoscopic surgery

• Commercialization at the international level

PARTNER COMPANY: EndoControl Medical• Spin‐off of the TIMC Lab, founded in 2006 in Grenoble

to design, develop and commercialize innovativerobotic solutions for laparoscopic surgery

• EndoControl raised €4M equity and is marketing itsproducts in the USA and Europe

• Contact: Clément VIDAL (CEO), www.endocontrol‐medical.com

13

Maj

HIFU: HIGH‐INTENSITY FOCUSED ULTRASOUND DEVICE FOR THE TREATMENT OF

Surgical Device Liver Metastasis from Colorectal Cancer Clinical POC Ongoing

CONCEPT• A High‐Intensity Focused Ultrasound (HIFU) device for the

treatment of non resectable liver metastases as a

LIVER METASTASES FROM COLORECTAL CANCER (€1,1 M)MAIN RESULTS

• Patented technology (Inserm‐Edap, 2005)l l f f h (treatment of non‐resectable liver metastases as a

complementary treatment to surgery• Added Value: 10 to 20% of patients are suitable for curative

surgery. HIFU may be used as a complementary tool tosurgery in order to increase the rate of treatment performedwith a curative intent

• Preclinical proof of concept with CLARA support (2007‐2009)

• Ethical committee and AFSSAPS agreement to start clinicalstudies (2009)

• Safety and feasibility validated in a Phase I/IIa clinicalwith a curative intent.HIFU advantages: Treatment is non‐invasive for the liver,independent from hepatic blood flow (allowing thetreatment of metastases that are currently unresectable),rapid and without limit in terms of size. Real‐timeultrasound imaging is used during treatment and offers a

y y /study on 15 patients (2010‐2011)

PROSPECTS• Phase IIb efficacy clinical study ongoing on 20 patients with

CLARA support (2012)ultrasound imaging is used during treatment and offers areliable visualization of the therapeutic intervention.

ACADEMIC/CLINICAL PARTNERS• D. MELODELIMA, J‐Y. CHAPELON, (Lab of Therapeutic

CLARA support (2012)

• Multicenter clinical trials, CE approval

• Ongoing developments: application to pancreatictumors, liver resection assisted by HIFU andextracorporeal treatment

Applications of Ultrasound, INSERM & UCBL1, Lyon)

• Pr M. RIVOIRE (Léon Bérard Cancer Center, ExperimentalSurgery Institute, Inserm, Lyon)

p

PARTNER COMPANY: EDAP TMSPARTNER COMPANY: EDAP TMS• Leader of therapeutic ultrasound, founded in 1979 in Lyon

(Nasdaq : EDAP)

• Contact : Emmanuel BLANC (CTO), www.edap‐tms.com

14

Maj

Immuno‐Monitoring Clinical POC OngoingMetastatic Breast and Lung Cancers

LYMPHOS1: Low TCR Diversity (Divpenia) Combined with Lymphopenia predicts poor Overall

CONCEPT• The “Number & Diversity of Lymphocytes" (NDL) score

based on combined measurement of lymphocyte count and

MAIN RESULTS 14/04/12• Patented technology (CEA, ImmunID Technologies, Léon

Bé d C C )

y ( p ) y p p p pSurvival in Metastatic Breast Cancer Patients (€850 K)

based on combined measurement of lymphocyte count andimmune TCR diversity measured by the ImmunTraCkeRplatform to detect immuno‐deficiency in patients witheither metastatic breast or lung cancer undergoingchemotherapy

• Added Value: Lymphopenia is observed in 20% of untreatedt t ti b t ti t d i i t d ith

Bérard Cancer Center)

• Lymphopenia or Lympho‐divpenia (NDL score 1) patientshave poor overall survival in metastatic Breast Cancercases

• Patients cohorts can be stratified to adapt chemicalmetastatic breast cancer patients and is associated with anincreased risk of early death partly due to chemotherapyimmunotoxicity: this test will allow the selection of patientsto adapt their treatment; it will also allow the developmentof innovation in immunotherapy and targeted therapies.

• Patients cohorts can be stratified to adapt chemicaltreatments like Avastin, Taxol or Taxoter

PROSPECTS• Prospective validation studies ongoing for metastatic

Breast and Lung Cancer Patients (2012)

ACADEMIC/CLINICAL PARTNERS• Pr J‐Y. BLAY (Léon Bérard Cancer Center, Lyon)

• C. CAUX, Ch. CAUX (Lyon Cancer Research Center)

g ( )• Clinical Assay Elypse 7 to measure the efficiency of IL7

treatment in metastatic breast cancer patients

PARTNER COMPANY: ImmunID Technologies• Emerging diagnostic company founded in 2005 as a spin‐off

of the CEA, specialized in combinatorial immune repertoireanalysis (services and kit commercialization) cy

te c

ount

ga

/L)

Low Risk

y ( )

• ImmunID Technologies raised €6M from public and venturecapital sources, and is searching for new public and/orprivate partners

• Contact: Nicolas PASQUAL (CEO), www.immunid.com

Lym

phoc

(Gig

hTRB VJ bi t i l

High Risk

hTRB VJ combinatorial diversity (%)

15

Maj

SYNFRIZZ: INNOVATIVE RADIO‐IMMUNOTHERAPY FOR SYNOVIALO‐SARCOMA TREATMENT

Radio‐Immunotherapy Clinical POC OngoingSynovialo‐Sarcoma

TARGETING FZD10, A TUMOR SPECIFIC ANTIGEN (€6.3M)CONCEPT

• Radio‐immunotherapy using a “first in man/first in class”

MAIN RESULTS• GMP‐antibody and radiolabeling process patented (OTS)• Preclinical POC achieved (OTS)

màj 04.07.12

humanized monoclonal antibody targeting a tumorspecific antigen, Frizzled‐10 (FZD10), radiolabeled with 90Ytrium

• Added Value: Orphan disease with no efficient systemictreatment in late stage cases

Preclinical POC achieved (OTS)• Antibody production process and radiolabeling validated• A first‐in‐man, first‐in‐class, randomized phase I open‐label,

two‐step, multicenter clinical trial authorized by AFSSAPS inOctober 2011

• Trial kick‐off in Léon Bérard Cancer Center and first patientinclusion in January 2012treatment in late stage cases

ACADEMIC/CLINICAL PARTNERS• Pr J‐Y. BLAY, Dr D. PEROL, Dr P. CASSIER, Dr I. RAY‐COQUARD

inclusion in January 2012• 4 patients recruited (June 2012)

PROSPECTS• Phase I clinical trial extension to Bordeaux (Institut

(Léon Bérard Cancer Center, Lyon)

PARTNER COMPANY: OncoTherapy Science (OTS)J bi h hi h F h R&D b idi

Phase I clinical trial extension to Bordeaux (InstitutBergonié) and Villejuif (Gustave Roussy Institute) CancerCenters

• Phase II clinical trial protocol design to start in 2014

• The approach will be extended to other indications:• Japanese biotech which set up a French R&D subsidiary

company in Lyon, in 2010

• Contact: Simon BACONNIER (CSO, OTS France),www.oncotherapy.co.jp/eng/

Gastric and colorectal cancers

16

Maj

ENKI‐HEH: NEW ENDOSCOPIC RESECTION DEVICE FOR SUPERFICIAL COLORECTAL, GASTRIC AND

Medical Device Clinical POC OngoingColorectal, gastric and esophageal

cancers

,ESOPHAGEAL NEOPLASMS (€350K)

CONCEPT• High pressure pulsed water jet system for endoscopic

b l

MAIN RESULTS• Patent (Nestis, 2010)

submucosal resection

• Added Value: Easy to use, faster, low risk of perforation,not reserved to expert surgeons

• CE Mark (September 2011)

• Preclinical Proof of concept validated on pigs’ colon (2012)

• ANSM agreement (April 2012)

• Clinical Proof of Concept on colorectal, esophageal and

ACADEMIC / CLINICAL PARTNERS• Pr. T. PONCHON (Lyon Civil Hospitals)

stomachal cancers (ongoing since June 2012)

PROSPECTS• FDA agreement (2012)

DEVELOPMENT PARTNER: Nestis• Created in 2010 (Lyon)

• Develop and market high pressure pulsed water jet

• Multicentric clinical study (Paris and Marseille)

• Establishment of Reference Centers in Europe for the use of Enki HEH technology in tumor resections

Develop and market high pressure pulsed water jetresection device

• Contact: Dr. Christian PINSET (President)

Enki‐II device used for endoscopicEnki II device used for endoscopicsubmucosal resection

17

Maj 25/09/2012

GENIUSVAC‐MEL4: THERAPEUTIC VACCINE BASED ON DENDRITIC CELLS TO TREAT

Cell Therapy Vaccine Clinical POC ScheduledMelanoma

METASTATIC MELANOMA (€1.7M)CONCEPT

• Innovative therapeutic vaccine based on allogeneicl ïd d d i i ll l d d i h 4 l

MAIN RESULTS• Cell lines, methods patented (EFS)

plasmacytoïd dendritic cells loaded with 4 melanomapeptides (MelanA, Gp100, Tyr and Mage‐3)

• Added Value: Allogeneic approach, one cell line forseveral patients, simple scaling‐up, low cost production,easy access treatment

• Preclinical POC achieved in 2010, in “humanized” murinemodel and ex vivo with patients immune cells

• Ethical Committee agreement December 9, 2011 for clinicaltrials

Cli i l k l d IMPD d i d i ll b ti itheasy access treatment

ACADEMIC/CLINICAL PARTNERS• J. PLUMAS (UJF‐EFS‐INSERM U823, Grenoble)

• Pr. M‐T. LECCIA and Pr. J‐L BOSSON (University Hospital

• Clinical work plan and IMPD designed in collaboration withCLARA experts to obtain AFSSAPS approval for phase I clinicaltrial (2012)

• GMP production of melanoma peptidesPr. M T. LECCIA and Pr. J L BOSSON (University HospitalCenter, Grenoble)

PARTNER COMPANY:French National Blood Service (EFS)

PROSPECTS• GMP production of a Master Cell Bank (2012)

• Phase I clinical trial: Kick‐off in 2012, to end in 2015

• POC in other therapeutic applications: Lung cancer, chronic( )• EFS main activity is blood transfusion. In France, EFS is the

leading supplier for human tissues and cells

• Involvement of the Cell Therapy Unit in Saint‐Ismier (nearGrenoble)

POC in other therapeutic applications: Lung cancer, chronicviral pathologies such as Hepatitis B, virus‐induced cancersuch as HPV+ cervical cancer …

• Contact: Joël PLUMAS (Project Manager) or Laurence LE TEXIER (TTO Director), www.dondusang.net

18

Maj

GANGLIOTOOL: MINI‐INVASIVE BIOPSY TOOL FOR NON‐LESIONAL CELLULAR AND PROTEIC FOOTPRINT

Diagnostic Device Preclinical POC CompletedLymphoma Metastatic Mediastinal Nodes

CONCEPT• A sampling device consisting of a hollow biopsy guide

with a lateral opening and a silicon chip with micro

OF TUMORAL NODES (€380K)MAIN RESULTS

• 6 patents (CEA, Inserm, UJF)with a lateral opening and a silicon chip with micro‐structures (pillars) with chemical surface modifications,capturing biological molecules and cells after appositionon a tissue (fingerprint).

• Added Value: Quantitative and qualitative improvements

• Ex vivo validation on extracted human nodes

• High quality validation of recovered micro samples bycytological techniques

• No toxicity of the modified surface detected in vitroof sampling and increase of patients comfort duringdiagnosis and therapeutic monitoring of malignancies,particularly for lymphoma, metastatic mediastinal nodesand tissue areas difficult to explore.

/

PROSPECTS• Clinical proof of concept with a multicentric clinical trial on

glioblastoma patients as of 2012 (Pr F. Berger, CEA/Clinatec)

• Developments for other tumor locations (such as sarcoma,l li ) i i d i b iACADEMIC/CLINICAL PARTNERS

• M‐L. COSNIER (CEA/LETI, Grenoble)

• Pr F. BERGER (CEA/Clinatec, Grenoble University Hospital,GIN), Pr G. SALLES (Lyon Civil Hospitals), Pr M. COTTIER, PrJ M VERGNON d P O TIFFET (S i t Eti U i it

lung, liver), peri‐tumor tissues, neurodegenerative brain,endoscopy, intravascular explorations…

• Diversification and extension of the technology may supportthe creation of a start‐up.

J.M. VERGNON and Pr O. TIFFET (Saint‐Etienne UniversityHospital)

PARTNER COMPANY: CEA‐Leti• CEA Laboratory based in Grenoble (MINATEC®) andy ( )

dedicated to applied research and transfer for health

• Contact: Raymond CAMPAGNOLO (Program Manager)www.leti.fr and Pr François BERGER (CLINATEC, GIN)

19

Maj

Imaging/Medical Device Preclinical POC CompletedSarcoma

CLARAFT: FLUORESCENCE IMAGING DEVICE FOR PEROPERATIVE DETECTION OF TUMOR MARGINS AND

METASTASIS IN SARCOMAS (€1M)CONCEPT

• A system to guide surgeons, combining a fluorescentb β ( ®) d

MAIN RESULTS• Instrumentation, imaging method (CEA, 2005, 2006, 2007)

d b dprobe targeting αvβ3 integrins (AngioStamp®) and a nearIR camera, for tumor margins and metastasesperoperative detection

• Added Value: Technology compatible with surgical unitlight, biodistribution specificity

and probe patented (Inserm/CNRS/UJF 2007)

• Detection with millimeter accuracy of tumor margins andlung metastases on rat osteosarcoma model and feline fibrosarcoma, preGMP probe regulatory toxicology harmlessnessin a cats.light, biodistribution specificity

ACADEMIC/CLINICAL PARTNERS• A. DUTOUR (Léon Bérard Cancer Center, Lyon)

J L COLL (Alb t B i t I tit t I J h

in a cats.

PROSPECTS• Multicentric Phase I/II clinical assay kick‐off (2012)

• J‐L. COLL (Albert Bonniot Institute, Inserm, JosephFourier University, Grenoble)

• Pr C. CAROZZO (VetAgroSup Veterinary School, Lyon)

PARTNER COMPANY Fl iPARTNER COMPANY: Fluoptics• CEA spin‐off created in 2009 in Grenoble: Development

and marketing of real time imaging systems to helphuman surgery, based on fluorescent probes and a minicamera

• Fluoptics raised a capital of €750K and is searching forFluoptics©

• Fluoptics raised a capital of €750K, and is searching forindustrial partners and/or investors.

• Contact: Odile ALLARD (CEO), www.fluoptics.com

Near InfraRed camera developed by Fluoptics

20

Maj 25/09/2012

NSH: HYBRID NANOPROBES AS IMAGING AGENTS TO TRACE CELLS IN THE COURSE OF CELLULAR

In vivo Imaging, Cell Therapy Preclinical POC CompletedMelanoma

CONCEPT

• Hybrid nanoparticles consisting of a magnetic core oflanthanide o ide coated b a pol silo ane shell as contrast

THERAPY PROTOCOLS IN MELANOMA (€615K)MAIN RESULTS

• No functional alterations of labeled cells observed in vitrolanthanide oxide coated by a polysiloxane shell as contrastagents to label cells for MRI tracing during cellular therapyprotocols

• Added Value: To help assess cell therapy protocols thatare rapidly developing in oncology but often show

and in vivo

• In vivo detection and quantification with MR imaging oflabeled cells in vivo after intraperitoneal and intravenousinjection (mouse)

• Capacity to produce nanoparticles of homogeneous sizep y p g gydisappointing clinical results; to help especially in thechoice of the administration route.

• Capacity to produce nanoparticles of homogeneous size

ACADEMIC/CLINICAL COORDINATOR

PROSPECTS• Clinical POC to be performed• Relevant for different cell therapy protocols and more/

• Dr C. BILLOTEY (Lyon Civil Hospitals, UCBL)extensively biotherapy (preventive and therapeuticvaccines, transplantation...)

DEVELOPMENT PARTNER: Nano‐HN bi h f d d i 2004 i ff f• Nanobiotech company founded in 2004 as a spin‐off ofLyon University to adapt, produce and commercializehybrid nanoparticles

• The project may finally be transferred to a companyi l d i th th ti k t t b f thinvolved in the therapeutic market to be furtherdeveloped in collaboration with Nano‐H.

• Contact: Cédric LOUIS (CEO), www.nano‐h.com Magnetic Resonance Imaging allows to detect in vivo withinthe spleen of a mouse (arrow) the labeled cells (right box) 24hours after its intravenous injection

21

Maj

CANCERDRUG : PRECLINICAL VALIDATION OF A NOVEL VASCULAR DISRUPTING AGENT (VDA)

Small Chemical Molecule Preclinical POC OngoingVascular Solid Tumors

( )TARGETING PP1 – PROTEIN PHOSPHATASE 1 (€1M)

CONCEPT • Development of D5 , a new chemical entity with VDA and

anti mitotic properties

MAIN RESULTS• D5 series patented (University of Grenoble, Curie

Institute CNRS 2010)anti‐mitotic properties• Added Value: D5 specifically targets PP1, is active per os

and shows a good toxicology profile; contrary to mostVDAs under development, D5 does not target tubulin andis likely to be better tolerated by patients.

Institute, CNRS, 2010)• Preclinical and clinical development planned (with the

help of CLARA experts)• Various human cancers evaluated in xenograft models to

identify those most sensitive to D5 (kidney, lung andthyroïd); D5 compared to the best‐in‐class reference VDA

ACADEMIC/CLINICAL PARTNERS• C.REMY, B. VAN DER SANDEN, F. BERGER (Grenoble

Neurosciences Institute, Inserm, University of Grenoble )

(CA4P); NMR allowed to predict/monitor D5 efficacy onblood flow in tumors; different administration schedules(iv, ip, per os) evaluated; unique dorsal chamber in vivomodel used to visualize/evaluate antivascular effects ofD5 and its analogues

, , y )

• Curie Institute, UMR176, Grenoble

PARTNER COMPANY: Ecrins Therapeutics• Biotech company, spin‐off of Grenoble Neurosciences

PROSPECTS• Regulatory toxicology and Phase I clinical trial (2013)

Institute, created in Grenoble in 2010. Ecrins Therapeutics isa drug discovery company, which develops a pipeline ofchemical anti‐cancer drugs. Ecrins Therapeutics has anexclusive licence on the D5 patent from the University ofGrenobleGrenoble

• Ecrins Therapeutics is looking for industrial partners orinvestors (€3M in 2012)

• Contact: Andrei POPOV (CEO),www.ecrins‐therapeutics.com Tumoral necrosis after D5 treatment

22

Maj

Therapeutic MAb Preclinical POC OngoingL.ymphomas

IPROMAH: IN VIVO PROOF OF CONCEPT OF HUMANIZED THERAPEUTIC MONOCLONAL ANTIBODIES

CONCEPT• In vivo Proof of concept of humanized monoclonal

antibodies targeting CD19 or CD5 for Non Hodgkin’s

FOR NON‐HODGKIN’S LYMPHOMA AGAINST CD19 OR AGAINST CD5 (€1M)MAIN RESULTS

• CD19: 2 patents, murine MAb selection and humanization,generation of humanized afucosylated anti CD19 MAb inantibodies targeting CD19 or CD5 for Non Hodgkin s

Lymphoma in association with chemotherapy

• Added Value #1 : Development of “best in class” anti‐CD19MAb as an alternative to Rituxan relapse or refractorytreatment

generation of humanized afucosylated anti‐CD19 MAb, invitro MAb potency (CDC, ADCC, PCD) PK/PD, preliminarytoxicity, in vivo mouse model efficacy in Rituxan refractoryhuman lymphoma, bioprocess for industrial bioproduction

• CD5: Murine MAb selection and humanization, in vitro MAb• Added Value #2 : Development of anti‐CD5 MAb as an

alternative to adverse effects Alemtuzumab (CD52)potency, in vivomouse model available

ACADEMIC / CLINICAL PARTNER• Pr C. DUMONTET (Lyon Civil Hospitals, Lyon University,

PROSPECTS• CD19 target: Completion of preclinical efficacy evaluation in

mono and combino therapy in 2012 in vivo POC related toPr C. DUMONTET (Lyon Civil Hospitals, Lyon University,Lyon Cancer Research Center)

mono‐ and combino‐therapy in 2012, in vivo POC related toautoimmune diseases, USP and DSP development

• CD5 target: in vivo POC to be completed in 2012PARTNER COMPANY: IDD Biotech

• iDD biotech is dedicated to the discovery andd l f h i l l ib di (MAb)

Anti CD19 MAb Efficacy in Rituximab Refractory Tumor Mouse Modeldevelopment of therapeutic monoclonal antibodies (MAb)

for the treatment of cancer, autoimmune diseases,inflammation or neurological disorders.

• With its proprietary hybridoma library and following MAbengineering, iDD biotech develops the next generation ofh i ib di

2000

2500

3000

3500

4000

olum

e (m

m3)

Model

Untreated

Rituximab

Anti CD19 MAb

therapeutic antibodies.• iDD Biotech is actively looking for industrial and/or

financial partners

• Contact : H. ROUQUETTE(CEO), C. DESROCHES (CSO) c.vermotdesroches@idd‐biotech.com

0

500

1000

1500

26 36 46

Tumor Vo

Number of days

IP injection (D26 D33 D40

23

c.vermotdesroches@idd biotech.com

Maj 25/09/2012

LANTHARAD: TARGETED HYBRID RADIOSENSITIZER NANOPARTICLES FOR RADIOTHERAPY OF

Nanoparticles for Radiotherapy Preclinical POC Ongoing,

Melanoma, Chondrosarcoma, Head and Neck, Gliosarcoma

CONCEPT• Solid hybrid nanoparticles based on rare‐earth such as

MELANOMA AND CHONDROSARCOMA (€615K)MAIN RESULTS

• Favorable biodistribution after iv injection of nanoparticleswith renal elimination and no liver or lung accumulationGadolinium, which specifically accumulates in tumors

after direct intra‐tumoral administration orintravenous administration, by either passive or activetargeting properties (specific vectors), and whichamplify the effect of radiation (radiosensitizer).

with renal elimination and no liver or lung accumulation• In vitro and in vivo radiosensitizing effect on human

radioresistant head and neck (SQ20B) xenograft model afterdirect intra‐tumoral injection of nanoparticles

• In vivo radiosensitizing effect (increase survival) in anth t i i l t d d l f i li ft i

p y ( )

• Added Value: Treatment of radioresistant tumors andpreservation of surrounding normal tissue

orthotopic implanted model of murine gliosarcoma after ivinjection

• Specific chondrosarcoma targeting after iv injection offunctionalized nanoparticles

ACADEMIC / CLINICAL PARTNERSP M JANIER (L Ci il H i l LPCML) PROSPECTS• Pr M. JANIER (Lyon Civil Hospitals, LPCML)

• Pr C. RODRIGUEZ‐LAFRASSE (Lyon Civil Hospitals,UCBL), Pr J.M. CHEZAL (Inserm U990, Clermont‐Ferrand), Pr O. TILLEMENT (LPCML, Lyon)

PROSPECTS• Clinical proof of concept of radiosensitizer nanoparticles on

head and neck radioresistant patients upon intra‐tumoraldirect administration

• Preclinical proof of concept of radiosensitizer targeting• Preclinical proof of concept of radiosensitizer targetingnanoparticles on a mouse chondrosarcoma modelPARTNER COMPANY: Nano‐H

• Nanobiotech company founded in 2004 as a spin‐offof Lyon University to adapt, produce andcommercialize hybrid nanoparticles

• The project may finally be transferred to a new or anexisting company to be further developed.

• Contact: Cédric LOUIS (CEO), www.nano‐h.com

In vivo proteoglycanes targetingwith vectorized nanoparticles, in an orthotopic chondrosarcoma

rat model

24

Maj

LIPOBAK B P O ASSOC P O O OSO S O G O S O T (€430K)

Therapeutic Biomolecule Preclinical POC OngoingGlioblastoma

LIPOBAK: BAK PROTEIN‐ASSOCIATED PROTEOLIPOSOMES FOR GLIOBLASTOMA TREATMENT (€430K)

CONCEPT• LipoBak is a lipidic vector that includes a therapeutic

MAIN RESULTS• Production process, products and applications patented

protein (Bak) and a glioblastoma targeting peptide.

• Added Value: Strong apoptotic effect, specific tumortargeting, no toxicity observed, versatile technology

(J‐L. LENORMAND, UJF, 2007). Targeting peptidepatented (Angers and McGill Universities, 2004)

• Large‐scale production of membrane proteins, optimizedliposomal composition, innovative grafting of homingpeptide preliminary results of efficacy demonstrated in

ACADEMIC/CLINICAL PARTNERS• Pr J‐L. LENORMAND (TheRex Laboratory, Joseph

Fourier University (UJF), Grenoble)

• Pr J. EYER (Neurobiology and Transgenesis Laboratory,

peptide, preliminary results of efficacy demonstrated invitro and in vivo on glioblastoma models

PROSPECTS• In vivo tests on xenograft murine brain tumor model

Angers)

PARTNER COMPANY: Synthélis• Grenoble based start‐up created in 2010, specialized in

In vivo tests on xenograft murine brain tumor model

• Non‐regulatory preclinical POC to be achieved in 2013

membrane protein production

• Selection for the Franco‐American NETVA program(New England Technology Venture Accelerator) todevelop Synthelis activity in the USA.

• Fund raising planned in 2012 to scale‐up theproduction process to GMP grade

• Contact: Bruno TILLIER (CEO), www.synthelis.fr Bak protein‐associated proteoliposome(Bak is represented in red)

25

Maj

NETRIS: DRUG CANDIDATES BASED ON DEPENDENCE RECEPTORS CONCEPT INHIBITING NETRIN‐1/

Anticancer Drug Candidates Preclinical POC OngoingPrimary Lung, Metastatic Breast Cancer

CONCEPT• Drug candidates that trigger apoptosis targeting Netrin‐

/DCC‐UNC5 IN LUNG CANCER (€810K) AND NT‐3/TRKC IN METASTATIC BREAST CANCER (€800K)

MAIN RESULTS• 2 patents, others in progress

1/DCC‐UNC5 in lung cancer and NT‐3/TrkC interaction inmetastatic breast cancer.

• Added Value: A new class of anticancer drugs based on adependence receptor concept discovered by Pr P. MEHLEN(Lyon Cancer Research Center) Autocrine over‐expression

• Ongoing development of several types of moleculesshowing promising preliminary results in terms of anti‐tumoral effect, toxicity and pharmacodynamics‐pharmacokinetic parameters in animal models

(Lyon Cancer Research Center). Autocrine over expressionof ligands of dependence receptors is found in severalcancers and plays an important role in the control oftumoral development.

PROSPECTS• Preclinical proof of concept of 2 drug candidates (2012)

• Other potential cancer indications: Prostate, liver,pancreas, colon, brain…

ACADEMIC / CLINICAL PARTNERS• P. MEHLEN, J.G. DELCROS and S. TAUSZIG‐DELAMASURE

(Lyon Cancer Research Center, Léon Bérard Cancer Center,Lyon)

Autocrine production of Netrin-1

PARTNER COMPANY: Netris Pharma• Spin‐off of Pr MEHLEN’s Laboratory (Lyon Cancer Research

Center) founded in 2008 to develop therapeutic candidatestargeting dependence receptor in cancertargeting dependence receptor in cancer

• Netris is searching for industrial and/or financial partners

• Contact: Agnès BERNET (CEO) and Pascale NONY (COO),www.netrispharma.com

Positive signalingproliferation, migration, survival

Negative signalingAPOPTOSIS

26

Maj

THERA 8: TARGETING CELL SURFACE CK8 FOR THE DEVELOPMENT OF THERAPEUTIC ANTIBODIES FOR

Therapeutic MAb Preclinical POC OngoingColorectal cancer

COLORECTAL CANCERS (€ 713K)MAIN RESULTS

• PCT Patent on the utilization of proprietary antibodies/

CONCEPT• Humanized monoclonal antibody targeting CK8 to reduce targeting CK8 to treat invasive and/or metastatic CRC

(WO/2010/136536)• Encouraging preliminary in vivo data on the efficacy of

mouse anti‐CK8 MAb

• Ongoing humanization of proprietary anti CK8 and

• Humanized monoclonal antibody targeting CK8 to reducedissemination of colorectal cancers (CRC) cells

• Added Value: therapeutic MAb dedicated to the reductionof the invasiveness of CRC cells combined with otherexisting anti‐cancer treatments

ACADEMIC/CLINICAL PARTNERS• JJ DIAZ, MA ALBARET(Lyon Cancer Research Center(CRCL))

• Ongoing humanization of proprietary anti‐CK8 andgeneration of new proprietary anti‐CK8 with severalimmunization methods

PROSPECTS• Preclinical proof of concept of the anti‐invasive and/or anti‐

g

PARTNER COMPANY: IDD Biotech• iDD biotech is dedicated to the discovery and

development of therapeutic monoclonal antibodies(MAb) for the treatment of cancer, autoimmune diseases,

• Preclinical proof of concept of the anti‐invasive and/or anti‐metastatic properties of the anti‐CK8 Mabs in mousemodels bearing human CRC xenografts (2014)

• Better understanding of the role of CK8 and its isoforms inthe invasive/metastatic processC did t l ti f li i l t finflammation or neurological disorders.

• With its proprietary hybridoma library and following MAbengineering, iDD biotech develops the next generation oftherapeutic antibodies.

• iDD Biotech is actively looking for industrial and/or

A fraction of the CK8 pool isdistributed in theintracellular compartmentwithin the intermediatefilament network (GFP‐CK8l b l d i ll ) h

• Candidate selection for clinical transfer

iDD Biotech is actively looking for industrial and/orfinancial partners

• Contact: H. ROUQUETTE(CEO), C. DESROCHES (CSO) c.vermotdesroches@idd‐biotech.com

labeled in yellow) whereasanother fraction of this poolis localized at the externalsurface of the cell (GFP‐CK8labeled in green andendogeneous CK8 labeled inred)

27

Maj 25/09/2012

red)

TRT/PET MEL: DEVELOPMENT OF HETEROAROMATIC HALOGENATED MOLECULES FOR EITHER

Imaging, Radioimmmunotherapy Preclinical POC OngoingMetastatic Melanoma

CONCEPT• Heteroaromatic halogenated molecules for melanin

d l b ll d h d f (18 )

/PET OR SPECT IMAGING AND TARGETED RADIONUCLIDE THERAPY OF METASTATIC MELANOMA (€830K)

MAIN RESULTS• Patent on (radio)chemical entities and their (radio)synthesis

targeting radiolabelled with radioisotopes for PET (18F) orSPECT (123I) imaging and for targeted radionuclide therapy(131I) of metastatic melanoma.

• Added Value: To perform (i) an early diagnosis and stagingof melanoma lesions by combining tracer specificity and

• Ongoing synthesis and preclinical evaluation of differentcandidates

PROSPECTS• Pharmacomodulation and structure‐activity relationshipof melanoma lesions by combining tracer specificity and

PET performance and (ii) a targeted radionuclide therapywith pre‐validated biodistribution

ACADEMIC/CLINICAL PARTNERS

studies in order to optimize metabolic andpharmacokinetics profiles

• Candidate selection for clinical transfer (2013)

• E MIOT‐NOIRAULT, J.M. CHEZAL (UMR 990 Inserm, Auvergne University)

PARTNER COMPANY: Cyclopharma Laboratories• Specialized European radiopharmaceutical company

founded in 2000 in Saint‐Beauzire, dedicated to thedevelopment and production of radiopharmaceuticals fornuclear medicine

• Contact: Pr Serge ASKIENAZY (Medical andResearch Director), www.cyclopharma.fr

One candidate selected : High tumor/background ratio, Early and specific PET imaging of melanoma in mice, Targeted Radionuclide Therapy after 131 I labeling: under evaluation in melanoma bearing mice

PREFET DE LA REGION AUVERGNE28

Maj

DOC CALIPSO RO O N G O O S T O FOC T (€1 3M)

Surgical Device Preclinical POC OngoingSmall Solid Tumors

DOC CALIPSO: ROBOT NAVIGATION FOR SMALL TUMOR FOCAL THERAPY (€1.3M)

CONCEPT• A robot with a tri‐dimensional navigation system guided

MAIN RESULTS• Robot patented (ADEPT)

by a patient’s implanted sensor, to position a focaltreatment probe for radiofrequence, cryotherapy, high‐intensity focused ultrasound or laser

• Added Value: Standardization, 1/10 mm accuracy, respectof adjacent organs less agressive technique

• Robotic development ongoing: Compatibility successbetween robot, operating table and instrumentation;neutral stand development ongoing, biocompatiblesensors identified

• Software development to correlate real time organ imagesof adjacent organs, less agressive technique

ACADEMIC/CLINICAL PARTNERS• Pr M. COLOMBEL (Lyon 1 Claude Bernard University,

• Software development to correlate real time organ imageswith RMI images, for probe positioning

• First robotic tests on soft tissues demonstrating thepositioning system accuracy

Pr M. COLOMBEL (Lyon 1 Claude Bernard University,Lyon Civil Hospitals)

PARTNER COMPANY: ADEPTd d h d

PROSPECTS• Robot preclinical transfer to realize probe implantation

tests in dead organs, in a pig model and in a human body

• Preclinical POC expected in 2013• Adept was created in 1983 in the USA, Adept

Technologie France in 1989, with R&D activity localizedin Annecy

• Leader in robot automated systems

• ADEPT is searching for a partner to industrialize Doc Calipsotechnology

• Contact: Bruno ADAM, www.adept‐technology.fr

DOC CALIPSO robot modeling

29

Maj 25/09/2012

HEPATOFLUO: INDOCYANINE GREEN AS A NEAR‐INFRARED FLUORESCENT CONTRAST AGENT AND

Imaging/Medical Device Preclinical POC OngoingLiver Cancer and Metastases

MINI‐CAMERA FLUOBEAM® FOR IMAGE‐GUIDED LIVER SURGERY (€1M)CONCEPT

• Per‐operative imaging system, based on Indocyanine( ) fl k d l b ®

MAIN RESULTS• Instrumentation and imaging method patented (CEA,

)Green (AMM) as a fluorescent marker, and a Fluobeam®mini‐camera

• Added Value: Improvement of per‐operative qualityimaging for image‐guided liver surgery, in order toidentify liver segments and tumorous lesions; technology

2005, 2006, 2007)

• Preclinical POC ongoing: Added value demonstration ofFluobeam® ‐ Indocyanine Green combination (to end in2012)

identify liver segments and tumorous lesions; technologycompatible with surgical unit light


PROSPECTS• Imaging camera optimization

• Clinical Trial submission and kick‐off (2013) in Léon Bérard Cancer Center

• Dr P. PEYRAT (Léon Bérard Cancer Center, Lyon)

PARTNER COMPANY: Fluoptics• CEA Spin‐off created in Grenoble in 2009: Development

d k i f l i i i h land marketing of real time imaging systems to helphuman surgery, based on fluorescent probes and a mini‐camera

• Fluoptics raised a capital of €750K and is looking forindustrial partners and investors

• Contact: Odile ALLARD (CEO) www fluoptics com• Contact: Odile ALLARD (CEO), www.fluoptics.com

Fluobeam®

30

Maj

NANO ENO N O C S N C /O C I G G P O (€700K)

Imaging/Biomolecule Preclinical POC OngoingSolid Tumors

NANO ENO: NANOENCAPSULATED NUCLEAR/OPTICAL IMAGING PROBE (€700K)

CONCEPT• Lipidots™, hybrid lipidic nanovector carrying both a

l (f ) d

MAIN RESULTS• Lipidots™ patented (CEA, 2007, 2008)

nuclear imaging agent (for PET or SPECT imaging) and anoptical imaging agent

• Added Value: Lipidots™ are organic, non toxic andbiodegradable. The bi‐modality will allow pre‐operativetumor identification and quantification, and per‐

• Bi‐modal nanocarrier optimization, physical and chemicalproperties characterization, quality control and in vitro testsongoing

tumor identification and quantification, and peroperative surgery guidance.

ACADEMIC/CLINICAL PARTNERSP BOISSEAU I TEXIER (CEA G bl ) B TAVITIAN (CEA

PROSPECTS• In vivo tests on breast murine cancer and dog models

planned for 2012 and 2013

• Preclinical POC to end in 2013• P. BOISSEAU, I. TEXIER (CEA Grenoble), B. TAVITIAN (CEA

Orsay)

• F. PONCE (VetAgroSup Veterinary School , Lyon)

PARTNER COMPANY:Advanced Accelerator Applications (AAA)

• AAA is a European pharmaceutical company set up in2002; its main activity is to develop either therapeutic ori i l l f i ’ d h Thimaging molecules for patients’ targeted therapy. TheFrench company is located in Saint‐Genis Pouilly.

• Contact: Stefano BUONO (CEO), www.adacap.com

31

Maj 25/09/2012

UROLINK A O C U O V S C A S O OS S S S P OS C C (€400K)

Surgical Device Preclinical POC OngoingProstate Cancer

UROLINK: AUTOMATIC URETRO‐VESICAL ANASTOMOSIS SYSTEM IN PROSTATE CANCER (€400K)

CONCEPT• UroLink is a mini‐invasive device designed to reconstruct

the bladder neck and reconnect it to the urethra by

MAIN RESULTS• Device patented

the bladder neck and reconnect it to the urethra bycircular suturing (anastomosis) after a radicalprostatectomy procedure.

• Added Value: Needles and bioresorbable wires, potentialreduction of postoperative side effects (impotence,incontinence or stenosis); safe fast and reliable

• Ex vivo feasibility POC on bladder and urethra

• Work plan established up to clinical trial

PROSPECTSincontinence or stenosis); safe, fast and reliableprocedure, adaptable to robotic surgery


PROSPECTS• Preclinical POC on pig models and device optimization

• CE marking procedure

• French monocentric Clinical trial submission and kick‐offfirst then European multicentric clinical trial to obtain

• Pr C. CAROZZO (VetAgroSup Veterinary School, Lyon)

PARTNER COMPANY: Anastom Surgical

first, then European multicentric clinical trial to obtainreimbursement.

• Anastom Surgical will be created in 2012, to developand bring UroLink on the market , as well as a portfolioof circular suturing devices based on the sametechnology.

• Contact: Arnold FERLIN (CEO)( )

Urethra sound Urolink main tool introduced inUrethra sound, Urolink main tool introduced in urethra to realize anastomosis

32

Maj

CLARA – CANCÉROPÔLE LYON AUVERGNE RHÔNE‐ALPES

CLARA’ d i t k i b dCLARA’s dynamic network is based on:

• 280 Academic Teams

• 80 Clinical Teams80 Clinical Teams

• 60 Innovative Enterprises• 4 University Hospital Centers• 2 Comprehensive Cancer Centers

• Centers of Excellence: LYRIC, DEVweCAN, C t I tit t CALYMCarnot Institute CALYM…

33

YOUR CONTACTS AT THE CANCÉROPÔLE CLARA

• Laurent LEVY, Finance and Development Director• llevy@canceropole‐clara.com

• Ophélie PHILIPOT, Project Manager “Transfer”Ophélie PHILIPOT, Project Manager Transfer• ophilipot@canceropole‐clara.com

www.canceropole-clara.com

35

ACKNOWLEDGEMENT TO CLARA PROOF OF CONCEPT PARTNERS

Public AuthoritiesPublic Authorities• European ERDF Funds, INCa, Rhône‐Alpes Region, Rhône Department, Greater Lyon, Isère

Department, Grenoble Metropole, City of Grenoble, Loire Department, Saint‐Etienne Metropole, Auvergne Region, Puy‐de‐Dôme Department, Clermont Community

Academic and Clinical Centers• University Hospitals: Lyon Civil Hospitals, Grenoble, Saint‐Étienne, Clermont‐Ferrand• Cancer Centers: Léon Bérard Cancer Center, Jean Perrin Center

R h C t L C R h C t (CCRL) Alb t B i t I tit t NEEL I tit t• Research Centers: Lyon Cancer Research Center (CCRL), Albert Bonniot Institute, NEEL Institute• Research Institutions: CEA Grenoble, CNRS, École des Mines of Saint‐Étienne, French Blood Institute,

INSA Lyon, INSERM, VetAgroSup• Universities: Claude Bernard Lyon 1, Joseph Fourier in Grenoble, Pierre Mendès France in Grenoble,

Auvergne UniversityAuvergne University

Companies• AAA, ADEPT, Anastom‐Surgical (Créalys incubator), CAVI‐T (Créalys incubator), CEA, CovalAb, EBV‐

Bi h E i Th i Ed TMS E d C l M di l EFS Rhô Al ERY h PhBiotech, Ecrins Therapeutics, Edap TMS, EndoControl Medical, EFS Rhône‐Alpes, ERYtech Pharma, Fluoptics, HLA‐G Technologies, iDD Biotech, ImmunID Technologies, Innate Pharma, LaboratoiresCyclopharma, Nanobiotix, Nano‐H, Nestis, Netris Pharma, OncoTherapy Sciences, Synthelis

36

Under the aegis of the Léa and Napoléon Bullukian Foundation

Portfolio CLARA Proof of Concept projects

Documents

Transcript of Portfolio CLARA Proof of Concept projects